Jose Ricardo Soares: Genomic Testing for All Patients Considered for Clopidogrel in UK
Jose Ricardo Soares, Relief Pharmacist at Uniphar Group, reposted from University of Liverpool on LinkedIn:
”Genomic testing for all patients considered for clopidogrel (before therapy starts). UK.
Clopidogrel empirically prescribed by doctors is not working in a staggering 29% of patients – being in those ineffective in prevention of stroke or MI.
Why: being a prodrug it must be activated via CYP 2C19 — patients with loss‑of‑function these CYP variants (intermediate/poor metabolisers) get much less antiplatelet effect and more thrombotic events.
So: the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics issued a guideline that recommends CYP2C19 genotyping for all patients in whom clopidogrel is being considered, “where testing is available”.
My opinion, this means that testing will soonly be available in secondary care units across the UK.
Moreover: the PGx (pharmacogenomics) data is stored as structured data into the shared electronic health record, information readily available to the prescribers (hospital, GP/community systems).
This way it will be a once in a lifetime test.
Looks quite futuristic for a patent-expired medicine.”
Quoting University of Liverpool‘s post:
”NEWS I: New UK guideline for clopidogrel recommends pharmacogenetic testing for all patients before prescription
The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, led by the University of Liverpool, has published its first clinical guideline focused on the use of the antiplatelet medication clopidogrel, widely prescribed in the UK to prevent blood clots. Pharmacogenomics looks at how differences in our genes can change the way medicines affect each person.
Find out more here.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Jul 5, 2026, 04:54Saneha Anjum Shaik: What Every Clinician Should Know Before Ordering Blood Tests
-
Jul 5, 2026, 04:37Mathis Richter: How The Bone Marrow Responds To Myocardial Infarction Predicts Clinical Outcome
-
Jul 5, 2026, 02:45Marie Luise Hütter-Krönke: Can a Short Course of BCMA-Targeted Therapy Induce Long-Term Remission in Refractory Autoimmune Disease?
-
Jul 5, 2026, 02:24Shreya Agarwa: Transforming Care For Adolescents With Heavy Menstrual Bleeding
-
Jul 4, 2026, 17:38Michael Stark: Greater Improvements in Cerebral Oxygenation With Restrictive Transfusion Thresholds
-
Jul 4, 2026, 17:27Reza Shojaei: How America Won the Plasma Race
-
Jul 4, 2026, 17:26Akshat Jain: The First CRISPR-Cas9 Gene Therapy Approved for Children as Young as 2 with SCD
-
Jul 4, 2026, 17:25Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
-
Jul 4, 2026, 17:24Thierry Burnouf: The Fragile Supply of Human Hyperimmune Immunoglobulins